Meta-analysis of the Efficacy of Immune Checkpoint Inhibitors in the Treatment of Extensive-disease Small-Cell Lung Cancer and Risk of Thyroid Dysfunction
Wang Yanling
Li Jing
Sun Jing
Abstract：Objective:To elevate the efficacy and development of immune-related Thyroid Dysfunction(ir-TD)in the treatment of extensive-disease small-cell lung cancer(ED-SCLC)with immune checkpoint inhibitors(ICIs).Methods:Studies on the treatment of ED-SCLC by ICIs from data set to August 2023 were searched from the PubMed,Embase,Cochrane Library,Web of Science and Scopus databases were included and analyzed in this studies.Results:6 studies with a total of 2 995 patients were selected from 951 articles and included in Meta-analysis.Compared with the control group,ICIs treatment significantly prolonged overall survival(HR:0.74,95%CI:0.68～0.81,P＜0.001)and progression free survival(HR:0.68,95%CI:0.60～0.78,P＜0.001),and the ORR(RR:1.11,95%CI:1.01～1.23,P=0.03)was also superior to that of the control group.However,treatment with ICIs significantly increased the risk of hypothyroidism(RR:5.80,95%CI:2.18～15.44,P=0.000 4)and hyperthyroidism(RR:2.76,95%CI:1.76～4.32,P＜0.001).Conclusion:ICIs can significantly improve the prognosis and prolong the survival of ED-SCLC patients,with a high safety,but it increases the risk of ir-TD.
Keywords：Immune checkpoint inhibitorsEfficacyThyroid dysfunctionSmall-cell lung cancerMeta-analysis
Publication Date：2025-01-29
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 131-135 )